PRESSORAHUB Logo

Trump Reclassifies Medical Marijuana Policy

Trump Reclassifies Medical Marijuana Policy — Politics

Trump moves medical marijuana to Schedule III, easing rules but stopping short of full legalization.

"Trump moves medical marijuana to Schedule III, easing rules but stopping short of full legalization."

U.S. Policy Shift on Medical Marijuana Donald Trump’s decision to reclassify medical marijuana marks a notable shift in U.S. drug policy, though it falls short of full legalization. The move changes marijuana’s classification from Schedule I, the most restrictive category, to Schedule III for state-licensed medical use, signaling official recognition of its medical value and easing some regulatory burdens.


Economic and Research Implications The reclassification brings significant benefits for cannabis-related businesses, particularly dispensaries, which can now deduct expenses on federal taxes—something previously prohibited. It may also make scientific research more accessible and potentially open limited pathways for international trade involving medical cannabis products.


Limits of the Current Change Despite these developments, the change applies only to medical marijuana. Recreational cannabis remains outside the scope of this reclassification, although a broader policy shift is still under consideration. A key administrative hearing is expected to determine whether similar adjustments could extend to the recreational market.


Ongoing Legal Conflicts Marijuana continues to be illegal at the federal level, creating tension with state laws where medical and recreational use are already permitted. This mismatch leads to complications for businesses operating across different regulatory systems, particularly when separating revenue streams for compliance and taxation purposes.


Debate Over Future Reform Supporters view the move as overdue recognition of cannabis’s medical benefits and a step toward modernizing outdated drug laws. Critics, including some health experts, caution that loosening restrictions could increase usage and downplay potential risks, especially as more potent cannabis products become widespread. For now, the reclassification represents a transitional step toward possible broader reform rather than a final resolution.